Regenxbio (RGNX) traded down -1.5 % during a 24 hours period ending at 03:40 AM Central Europe on Wednesday 28th. One Regenxbio stock can currently be bought for about USD 6.6 on popular exchanges. Current supply of Regenxbio stocks is 66.2 mn. Regenxbio has a current market capitalization of USD 446.9 mn and approximately USD 7.5 mn worth of Regenxbio was traded on exchanges in the last 24 hours. Since last month end, Regenxbio has traded -11.91 % down. Simple moving average of last 200 days is at USD 9.33. The highest price of past 52 weeks was recorded at USD 16.19 on 01/22/2026. 52 weeks low was at USD 5.46 on 05/18/2026.

Here is how related stocks have performed in the past 24 hours:

  • Titan Machinery (TITN) traded down -0.22 % and now trades at USD 23.29. Titan Machinery has a market capitalisation of USD 536 mn.

  • Bankwell (BWFG) traded up 0.03 % and now trades at USD 66.84. Current market capitalisation for Bankwell is USD 528.5 mn. Current price/earnings ratio for Bankwell is 12.49.

  • Northpointe Bancshares (NPB) traded down -1.36 % and now trades at USD 15.76. Northpointe Bancshares has a market capitalisation of USD 533.9 mn. Current price/earnings ratio for Northpointe Bancshares is 6.81.

  • Wabash National (WNC) traded up 0.78 % and now trades at USD 13.79. Current market capitalisation for Wabash National is USD 536.1 mn.

  • Pangaea Logistics (PANL) traded up 1.13 % and now trades at USD 7.98. Current market capitalisation for Pangaea Logistics is USD 528.3 mn. Pangaea Logistics has a current price to earnings ratio of 10.9.

About Regenxbio

The biotechnology company REGENXBIO Inc. specializes in the development, commercialization, and licensing of recombinant and adeno-associated virus gene therapy. Their mission is to revolutionize the way patients with genetic disorders are treated by providing innovative solutions that leverage the power of gene editing technologies. REGENXBIO operates globally, with its main base located in Rockville, United States. You can learn more about their offerings and initiatives by visiting their website at www.regenxbio.com . They went public on the Nasdaq stock exchange on September 17, 2015.